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Abstract
Background: Flavonoids are a diverse family of natural phenolic compounds commonly found in fruits and
vegetables. Epidemiologic studies showed that flavonoids also reduce the risk of colon cancer. Tectochrysin is one
of the major flavonoids of Alpinia oxyphylla Miquel. However, the anti-cancer effects and the molecular mechanisms
of tectochrysin in colon cancer cells have not yet been reported. We investigated whether tectochrysin could inhibit
colon cancer cell growth at 1, 5, 10 μg/ml. In in vivo study, we injected a tectochrysin treatment dose of 5 mg/kg
to each mouse.
Results: Tectochrysin suppressed the growth of SW480 and HCT116 human colon cancer cells. The expression of DR3,
DR4 and Fas were significantly increased, and pro-apoptotic proteins were also increased. Tectochrysin treatment also
inhibited activity of NF-κB. A docking model indicated that tectochrysin binds directly to the p50 unit. In in vivo, tumor
weights and volumes in mice were reduced when treated with tectochrysin. Tectochrysin leads to apoptotic cell death
in colon cancer cells through activation of death receptors expression via the inhibition of NF-κB.
Conclusions: Tectochrysin can be a useful agent for the treatment of colon cancer cell growth as well as an adjuvant
agent for chemo-resistant cancer cells growth.
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Background
Colon cancer is the third most commonly diagnosed can-
cers in the world [1], with an estimated 140,000 new cases
and over 50,830 deaths in 2013 in the USA, and over 1.2
million new cases and 600,000 deaths worldwide [2]. Sur-
gery, radiotherapy and chemotherapy are used for treating
colon cancer patients [3]. However, those treatments are
not sufficient because of resistance against chemotherapy,
toxicity and side-effects. Therefore, it is urgent to develop
novel anti-cancer agents with fewer side effects to satisfy
the unfulfilled therapeutic demands of patients.
Apoptosis plays an important role in anti-cancer effects
of chemotherapeutics [4]. Apoptosis can be induced by
stimulation of death receptor (DRs) [5]. Binding to their
respective ligands, DRs are activated and recruit the intra-
cellular adaptor protein (Fas-associated death domain
protein) which results in the activation of caspase-3,
caspase-8 and caspase-9 as well as Bax to kill cancer cells
[6]. Chemo-resistances are also related to the expression
of DRs in colon cancer cells [7]. Therefore, DR-mediated
apoptosis has emerged as an effective strategy for cancer
therapy. Several compounds have demonstrated the
anticancer effects through activation of DRs. Baicalein, a
naturally occurring flavonoid, enhanced TRAIL-induced
apoptosis via increase of DR5 expression [8]. Casticin, a
flavonoid, induced apoptosis through stimulation of the
expression of DRs in colon cancer cells [9]. Nuclear
factor-κB (NF-κB) represents a family of eukaryotic tran-
scription factors participating in the regulation of various
cellular responses involved in apoptosis [10]. NF-κB plays
a regulatory role in the expression of an array of apoptotic
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(caspase-3 and Bax), anti-apoptotic (Bcl-2 and IAP
family), and cell proliferation gens (cylooxygenase-2 and
cyclins) [11]. NF-κB is constitutively activated in human
colorectal carcinoma tissue and colon cancer cells [12].
From this knowledge, NF-κB can be specifically targeted
to prevent colon cancer cell growth. Several of our studies
have demonstrated that compounds inhibiting NF-κB
have shown to be useful for inhibition of colon cancer cell
growth. 4-O-methylhonokiol and inflexinol inhibited
colon cancer cell growth through suppression of NF-κB
pathway [13, 14]. Furthermore, the activation of NF-κB in
response to chemotherapy is a principal mechanism of in-
ducible chemo-resistance [15–18]. Thus, inactivation of
NF-κB is intended as a strategy to eliminate cancerous cells.
Flavonoids are a diverse family of natural phenolic
compounds commonly found in fruits and vegetables
[19]. It is classified as flavonols, flavonones, flavans, etc.
Flavonoids especially display a wide range of pharmaco-
logical properties including anti-inflammatory, anti-
mutagenic, anti-carcinogenic and anti-cancer effects
[20]. An epidemiologic study also showed that flavonoids
reduce the risk of colon cancer [21]. Several studies have
reported that some flavonoids have direct effects on
apoptosis in colon cancer cell. Luteolin, a type flavonoid,
has effects on apoptosis of colon cancer cells [22]. An-
other flavonoid, chrysin, also suppressed cancer cell
growth through inhibition of the expression of NF-κB in
colon cancer cells. Alpinia oxyphylla Miquel is used for
treating intestinal disorders, dieresis, uresis, ulceration
and diarrhea [23]. Yakuchinone A and yakuchinone B
existed in Alpinia oxyphylla Miquel (Zingiberaceae) have
anti-cancer effects in skin carcinogenesis [24]. Tecto-
chrysin, another flavonoid compound, is isolated from
Alpinia oxyphylla Miquel. Our previous study showed
that tectochrysin suppressed lung cancer cell growth via
inactivation of STAT3 [25]. Moreover, our preliminary
study showed that tectochrysin was found to bind NF-κB.
However, the anti-cancer effects and the molecular mech-
anisms of tectochrysin in colon cancer cells have not yet
been reported. Thus, in this study, we investigated
whether tectochrysin could inhibit colon cancer cell
growth via suppression of NF-κB activity and enhance-
ment of DR expression in in vitro and in vivo.
Results
Effect of tectochrysin on cell growth and apoptosis
cell death
To assess the inhibitory effect of tectochrysin on cell
growth of colon cancer cells (SW480, HCT116), we ana-
lyzed cell viability by MTT assay. The cells were treated
with varying concentrations of tectochrysin (1, 5, 10 μg/mL)
for 24 h. As shown in Fig 1a, tectochrysin inhibited cell
growth in colon cancer cells in a concentration-dependent
manner. Tectochrysin inhibited SW480 cells growth with
IC50 value of 6.3 μg/mL and HCT116 cells growth with
IC50 value of 8.4 μg/mL. Morphologic observation showed
that the cells were reduced in size by the treatment of tecto-
chrysin (10 μg/mL) in SW480 cells and HCT116 cells.
However, tectochrysin was not cytotoxic in the normal
CCD-18co cells in the tested concentration by MTT assay
(Fig. 1b). To delineate whether the induction of apoptotic
cell death is critical for cell growth inhibition by tectochry-
sin, we evaluated changes in the chromatin morphology of
cells using DAPI staining. To further characterize the apop-
totic cell death by tectochrysin, we performed TUNEL
staining assays, and then the labeled cells were analyzed by
fluorescence microscopy. Apoptotic cells number (DAPI-
positive TUNEL stained cells) in SW480 cell was increased
to 1 and 58 % by 0 and 10 μg/mL tectochrysin, respectively,
and 1 and 54 % by 0 and 10 μg/mL tectochrysin in
HCT116 (Fig. 1c).
Effect of tectochrysin on the expression of apoptosis
regulatory proteins and the expression of DRs
The relationship between the induction of apoptotic cell
death by tectochrysin and the expression of apoptosis
related protein was investigated. In agreement with the
induction of apoptotic cell death, expression of apoptotic
proteins such as cleaved caspase-3, -8, -9, cleaved PARP,
Bid, cytochrome-C and Bax was increased, but expres-
sion of Bcl-2, cIAP1 and XIAP was decreased in both
SW480 and HCT116 colon cancer cells in a concentra-
tion dependent manner (Fig. 2a). The extrinsic pathway
of apoptotic cell death requires induction of DRs expres-
sion. Moreover, expression of DRs is critical for activa-
tion of caspase-3. Therefore, we investigated the effect
of tectochrysin on the expression of DRs. The expression
of DR3, DR4 and Fas was highly induced by tectochrysin
in a concentration-dependent manner in both SW480
and HCT116 colon cancer cells (Fig. 2b), but expres-
sions of other DRs were not changed (data not shown).
Our data indicated that tectochrysin induced intrinsic
apoptosis by elevation of the BAX/BCL2 ratio, cytochro-
meC and cleaved caspase-3 and-9, and extrinsic pathway
by increase of death receptors and cleavage caspase-8.
Thus, Tectochrysin may act both intrinsic apoptosis and
extrinsic apoptosis pathway.
Effect of tectochrysin on NF-κB activation
Since highly activated NF-κB is an implicated factor in
cell survival as well as in the resistance against therapeu-
tics of colon cancer cells, we determined the inhibitory
ability of tectochrysin on the DNA binding activity of
NF-κB. We found a higher level of constitutive activa-
tion of the NF-κB in the untreated cells. However, the
treatment of tectochrysin (1, 5, 10 μg/mL) for 1 h inhib-
ited the constitutively activated DNA binding activity of
NF-κB in a concentration-dependent manner. We also
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found that tectochrysin concentration-dependently inhib-
ited the translocation of p50 and p65 into the nucleus
through inhibition of the phosphorylation of IκB (Fig. 2c).
Abolishing effect of DR3, DR4 and Fas siRNA on the
tetochrysin induced growth inhibition, apoptosis,
expression of apoptosis regulatory proteins and NF-κB
In order to investigate involvement of DR3, DR4 and Fas
in the tectochrysin-induced cancer cell growth, the effects
of DR3, DR4 and Fas siRNA on tectochrysin (5 μg/mL)-
induced cell growth inhibition was analyzed by MTT
assay. Transfection of DR3, DR4, Fas siRNA abolished the
cell growth inhibitory effect of tectochrysin on colon can-
cer cells (Fig. 3a). In agreement with these findings, the
decreased expression of cleaved caspase-3 protein by tec-
tochrysin (Fig. 3b) and DNA binding activity of NF-κB by
tectochrysin were also abolished in SW480 and HCT116
colon cancer cells treated with DR3, DR4 and Fas siRNA
(Fig. 3c).
Interaction between tectochrysin and NF-κB
The interaction of tectochrysin-epoxy Sepharose beads
with p50 recombinant protein or cell lysate containing
p50 protein was assessed using a pull-down assay. The
interaction of tectochrysin-epoxy Sepharose beads with
p50 was then detected by immunoblotting with anti-p50
antibody. The results indicated that tectochrysin (Fig. 4a)
interacted with recombinant p50 protein or cell lysates
containing p50 from SW480 treated with tectochrysin
(Fig. 4b). To identify the binding site of tectochrysin to
p50, we performed computational docking experiments
with tectochrysin and p50. The docking study showed
that tectochrysin forms two hydrogen bonds with
Gly365 and Val412 of the p50 unit on the amide back-
bone (binding affinity = -7.6 kcal/mol). It is further
surrounded by neighboring hydrophobic amino acid
residues such as Val358, Phe353, Ser363, Leu437, and
Leu440. Many of these residues are from β-sheets and a
loop near DNA binding areas, which may interfere with
the DNA binding to the dimeric NF-κB (Fig. 4c). Muta-
tion of Gly365 did not make any difference in binging
affinity between tectochrysin and hydrogen bond of p50,
but replacing Val412 has a stronger of binding affinity
because mutation of this amino acid residue disrupts
van Der Waals packing interaction between tectochrysin
and p50. Thus, to further determine the direct binding
effect of Val412 of p50 with tectochrysin, p50 mutant
plasmid (Vp50A) was transfected into SW480, and
checked cell growth and NF-κB activity. As expected,
tectochrysin did not inhibit the growth of colon cancer
Fig. 1 Effect of tectochrysin on cell growth and apoptotic cell death in colon cancer cells. a Concentration-dependent effect of tectochrysin on
the cell growth in SW480 and HCT116 cells. After treatment of tectochrysin (1, 5 and 10 μg/mL) for 72 h, the effect of tectochrysin on colon cancer cell
growth was determined by MTT assay and morphologic observation. b Concentration-dependent cell growth inhibitory effect of tectochrysin in
CCD-18co normal colon cell. After treatment of tectochrysin (1, 5 and 10 μg/mL) for 72 h, the cytotoxicity effect of tectochrysin on normal colon cell
viability was determined by MTT assay. c The colon cancer cells were treated with tectochrysin (1, 5 and 10 μg/mL) for 24 h, and then labeled with
TUNEL solution. The green color in the fixed cells marks TUNEL-labeled cells. Total number of cells in a given area was determined by using DAPI
nuclear staining (fluorescent microscope). The apoptotic index was determined as the DAPI-stained TUNEL-positive cell number/total DAPI-stained cell
number (magnification, 200x). These data are expressed as the mean ± SD of three experiments. *P < 0.05 indicates statistically significant differences
from the control group
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cell transfected with mutant p50 (Fig. 4d). EMSA also
showed that tectochrysin did not completely inhibit NF-
κB activity (Fig. 4e). These results clearly suggested that
tectochrysin mediates its effects through binding to Val
412 residue of the p50 subunit of NF-κB.
Combination effect of tectochrysin and TRAIL in
TRAIL-resistant cancer cell growth
The human colon cancer cell lines SW480 and HCT116
are known to be TRAIL-sensitive, while HT-29 (human
colon cancer cell), A549 (human lung cancer cell) and
MCF-7 (human breast cancer cell) are TRAIL-resistant
[26]. The aim of this study was to investigate whether
tectochrysin can enhance the sensitivity of TRAIL resist-
ant cancer cells to TRAIL and possible mechanisms. We
treated these cancer cells with half a dose of IC50 tecto-
chrysin (3 μg/mL) and TRAIL (50 ng/mL), and we found
that tectochrysin and TRAIL treatments alone induced
18.1 % and 9.6 % cell growth inhibition in HT-29 cells,
21.7 % and 7.1 % in A549 cells and 17.1 % and 20.8 % in
MCF-7 cells. However, a combination treatment with
tectochrysin and TRAIL enhanced TRAIL induced cell
growth inhibition up to 49.6 % in HT-29 TRAIL-
resistant colon cancer cells, 40.7 % in A549 TRAIL-
resistant lung cancer cells and 46.8 % in MCF-7 TRAIL-
resistant breast cancer cells (Fig. 5a). The combination
index values of A549 and HT-29 cells were 0.021, and
MCF-7 cells was 0.034. These data indicate that tecto-
chrysin leads to a synergistic growth inhibitory effect in
TRAIL-resistant cancer cells with TRAIL. In addition,
we compared the effect of tectochrysin and/or TRAIL of
the activation of caspase-3 and the expression of DR4 in
the TRAIL-resistant cancer cells. Although tectochrysin
and TRAIL alone had little effect on activation of
caspase-3 cleavage and DR4 expression, the combination
treatment significantly increased expression of cleaved
caspase-3 and DR4 (Fig. 5b). Tectochrysin also further
reduced DNA binding activity of NF-κB as well as trans-
location of p50 in the nucleus and cytosolic p-IκB
expression in TRAIL-resistant cancer cells (Fig. 5c).
Effect of tectochrysin on the colon tumor growth in in
vivo xenograft model
To elucidate the antitumor effects of tectochrysin in in
vivo, the tumor growth in colon cancer xenograft–bear-
ing nude mice following tectochrysin treatments was
Fig. 2 Effect of tectochrysin on the expression of apoptosis regulatory proteins and death receptors, and activation NF-κB in colon cancer cells.
The colon cancer cells were treated with different concentrations of tectochrysin (1, 5 and 10 μg/mL) for 24 h or for 1 h (for NF-κB assay). Equal
amounts of total proteins (20 μg/lane) were subjected to 10 % or 15 % SDS-PAGE. a Expression of cIAP1, XIAP, Bax, Bcl-2, Bid, Cyto-C, cleaved
caspase-3, -8, -9, cleaved PARP and β-actin was detected by Western Blotting using specific antibodies. b Expression of DR3, DR4, Fas, and β−actin
was detected by Western blotting using specific antibodies. c Activation of NF-κB was investigated using EMSA as described in Methods. After,
the cells were treated with different concentrations (1, 5 and 10 μg/mL) of tectochrysin at 37 °C for 1 h, nuclear or cytosolic proteins were
extracted and the expression of p50, p65, IκB-α, and p-IκB-α proteins was detected by Western blotting using specific antibodies. β-actin and
histone-H1 proteins were used as internal controls. Each band is representative for three experiments. Values below the band are average of
band density. (CE: cytosolic extraction, NE: nuclear extraction)
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investigated. In HCT116 xenograft studies, tectochrysin
was administrated i.p. twice per week for 3 weeks to
mice with tumors ranging from 200 to 300 mm3 in vol-
ume. The mice were weighed twice per week. The
changes in body weights between the control and the
tectochrysin-treated mice (n = 10) were not remarkably
different during the experiment (data not show). How-
ever, Fig. 6a showed the relative tumor growth delay
measured after the treatment of tectochrysin in com-
parison with the vehicle group. On day 21, the final
tumor weights were recorded. Tumor weights and vol-
umes in mice treated with tectochrysin at 5 mg/kg
doses were 57.9 % and 46.4 % of the vehicle group, re-
spectively (Fig. 6a). In agreement with the in vitro re-
sults, expression of cleaved caspase-3, DR3 and DR4
was significantly increased in the tumor tissues treated
with tectochrysin (Fig. 6b). DNA binding activities of
NF-κB and translocation of p50 and p65 into nucleus
were clearly lowered in tumor tissues treated with tec-
tochrysin (Fig. 6b and c). The immunohistochemical
analysis of tumor sections by H&E and by proliferation
antigens against PCNA, cleaved caspase-3 and DR3
staining revealed that tectochrysin inhibited tumor
growth (Fig. 6d).
Discussion
Recent evidence indicates that NF-κB signaling pathway
is significantly involved in tumor development [27]. The
constitutively activated NF-κB transcription factor has
been associated with several aspects of tumorigenesis
such as tumor cell growth, anti-apoptosis, metastasis,
angiogenesis, resistance against chemotherapeutics, and
tumor promotion in many cancer cells including colon
cancer [28]. The NF-κB transcription factor is constitu-
tively activated in human colorectal carcinoma tissue
and colon cancer cells to give favorable circumstance for
cancer cell growth [12, 29]. There have been many re-
cent reports demonstrating anti-cancer effects of several
compounds through inactivation of NF-κB. Our previous
studies also showed that compounds inhibiting NF-κB
activity such as 4-O-methylhonokiol and inflexinol
inhibited colon cancer cell growth [30, 31, 14, 13]. Several
studies have especially showed that flavonoids inhibit
colon cancer growth through inactivation of NF-κB. For
example, Methyl 3,5-dicaffeoyl quinate (200 μg/mL), a fla-
vonoid glucoside, induced cell cycle arrest and apoptosis
by inhibiting NF-κB activation in HT-29 human colon
cancer cells [32]. Furthermore, the flavonoids inhibited
other cancer growth via inactivation of NF-κB. Quercetin,
Fig. 3 Effect of DRs siRNA on the tectochrysin-induced colon cancer cell growth inhibition, expression of cleaved caspase-3 and NF-κB inactivation.
a The colon cancer cells were transfected with targeting DR3, DR4, and Fas siRNA (100 nM) for 24 h, and then treated with tectochrysin for 24 h. Then,
the cells were determined by MTT assay. The results were expressed as a percentage of viable cells. The data are expressed as the mean ± SD of three
experiments. *P < 0.05 compared with the untreated control. #P < 0.05 compared with the treated control. b Expression of cleaved caspase-3 and
β-actin was detected by Western Blotting using specific antibodies. β-actin proteins were used as internal controls. c The activation of NF-κB was
investigated using EMSA as described in Methods. Each band is representative for three experiments. Values below the band are average of
band density
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a principal flavonoid compound in onions, inhibits human
oral cancer cells through inhibition of NF-κB [33]. We, in
the present study, found that tectochrysin inhibited consti-
tutively activated NF-κB in colon cancer cells and colon
cancer tissues in xenograft animal model. In in vitro,
tectochrysin prevented NF-κB target anti-apoptosis gene
expression (but increased apoptosis gene expression) and
inhibited DNA binding activity of NF-κB. In in vivo, the im-
munohistochemical analysis of tumor section by p50 stain-
ing revealed that translocation of p50 into nucleus was
significantly lowered in the tumor tissues treated with tecto-
chrysin. We also found that tumor tissues treated with tec-
tochrysin inhibited the activated DNA binding activity of
NF-κB. Thus, it is possible that alteration in the expression
level of NF-κB target anti-apoptotic and pro-apoptotic pro-
teins is likely to influence apoptotic cell death by tectochry-
sin. These data indicates the possibility that tectochrysin
may inhibit NF-κB, thereby inhibit colon cancer cell growth.
Thus, tectochrysin, like other flavonoid compounds, could
be effective for the treatment of colon cancer cells.
In further chemical target identification studies, the
interaction of tectochrysin-epoxy-sepharose 6B beads
with NF-κB p50 protein was assessed using a pull-down
assay. The interaction of tectochrysin-epoxy-sepharose
6B beads with NF-κB p50 was then detected by im-
munoblotting with anti-NF-κB p50 antibody. The results
indicated that tectochrysin interacted with NF-κB p50.
To identify the binding site of tectochrysin to NF-κB
p50, we performed computational docking experiments
with tectochrysin and NF-κB p50. Tectochrysin forms
two hydrogen bonds with Gly365 and Val412 of the p50
subunit on the amide backbone. It is further surrounded
by neighboring hydrophobic amino acid residues such
Val358, Phe353, Ser363, Val412, Leu437 and Leu440.
Many of these residues are from β-sheets and a loop
near DNA binding areas, which may interfere with the
DNA binding to the dimeric NF-κB. Our previous studies
reported that inflexinol and snake venom toxin modifies a
cysteine residue and cysteine62 of p50 in NF-κB via direct
interaction of these sites, and thus inhibited the DNA
Fig. 4 Structural interaction between tectochrysin and NF-κB. a Structure of tectochrysin. b Pull-down assay identifies an interaction between
the tectochrysin and NF-κB p50. Tectochrysin was conjugated with epoxy-Sepharose 6B as described in Methods. c Docking model of
tecotochrysin with NF-κB p50 as described in Methods. d The p50 mutant cells were treated tectochrysin for 24 h, and then analyzed by MTT
assay. The data are expressed as the mean ± SD of three experiments. *P < 0.05 compared with the untreated control. #P < 0.05 compared with
treated control. e SW480 colon cancer cells were transiently transfected with control or mutant types of p50 for 24 h as described in Methods,
and then the cells were treated with tectochrysin for 1 h to determine DNA binding activity of NF-κB. Values below the band are average of
band density
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binding activity of NF-κB [14, 34]. Another study also
showed that kaurane diterpene inhibited NF-κB directly
targeting the DNA-binding activity of cysteine62 in p50
[35]. Moreover, the abolished effect on growth inhibition
and inactivation of NF-κB in colon cancer cells transfected
a p50 mutant (Vp50A, Valine412 was substituted with
Alanine) were observed after a treatment with tectochry-
sin. Therefore, these data indicate that tectochrysin in-
hibits colon cancer cell growth through inactivation of
NF-κB by direct binding on Val412 residue of p50.
DRs are the cell surface receptors that are a part of
tumor necrosis factor (TNF) members of cytokines. It is
well-known that apoptosis can be induced by stimula-
tion of DRs including TNFR1/2, DR3, DR4, DR5, DR6
and Fas by their respective ligands [36]. Therefore, these
receptors emerged as attractive targets for anti-cancer
therapeutics. Several compounds induced apoptotic cell
death of cancer cells through increasing DR expression.
Our previous study showed that snake venom toxin
induced apoptosis of HCT116 and HT-29 colon cancer
cells via enhancement of DR4 and DR5 expression [26].
Flavonoid, such as fucoidan, increased apoptosis of hu-
man colon cancer cells via increased expression of DR4,
DR5 and Fas [37]. Flavonoid compounds are also known
to have an anti-cancer effect through activation of DR-
caspase pathways. Caspases play a critical role in apop-
tosis by DRs [38]. Hesperetin, a flavonoid from citrus
fruits, exhibited a potential anticancer activity against
human cervical cancer cell lines through the induction
of apoptosis via caspase-3 activation by increasing Fas
expression [39]. Genistein, one of well-known isofla-
vones, enhanced apoptosis in lung cancer cells induced
by increasing the expression of cleaved caspase-3 via
up-regulation of TNFR-1 DR signaling [40]. Other com-
pounds such as grape seed extract inhibited human
colon cancer cell growth by increasing caspase-3 [41].
Fig. 5 Effect of tectochrysin on cell growth, DR4 and cleaved caspase-3 expression, and NF-κB activity in TRAIL-resistant cancer cell. a HT-29,
A549, and MCF-7 cells were pretreated with tectochrysin (3 μg/mL) for 24 h, the media were removed, and the cells were exposed to TRAIL
(50 ng/mL in HT-29, A549, and MCF-7 cells) for 24 h. The effect of tectochrysin on resistant cancer cell growth was determined by MTT assay. The
data are expressed as the mean ± SD of three experiments. *P < 0.05 compared with the control. #P < 0.05 compared with the treated TARIL
treated cells. b Expression of DR4, p-IκB, IκB, p50, β-actin and histone-H1 was detected by Western blotting using specific antibodies. β-actin and
histone-H1 proteins were used as internal controls. c The activation of NF-κB was investigated using EMSA as described in Methods. Each band is
representative for three experiments. Values below the band are average of band density
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Similar to these results, our results showed that the ex-
pression of DR3, DR4, Fas and cleaved caspase-3 and -9
highly increased by tectochrysin in a concentration-
dependent manner. Moreover, knock down of DR3, DR4
and Fas with siRNA abolished the growth inhibitory ef-
fect and caspase-3 activation of tectochrysin on colon
cancer cells. In a previous study, we found that tecto-
chrysin inhibited lung cancer cell growth via overexpres-
sion of DR3 and Fas [25]. These data demonstrated that
depending on the different cancer type, differential DR
pathway may be significant. These results indicate that
the colon cancer cell growth inhibitory effects of tecto-
chrysin could be related caspase-3 pathway linked to
DR3, DR4 and Fas.
NF-κB inhibition could also be effective to overcome
chemo-resistance [42]. Our previous study reported that
natural snake venom toxin suppressed TRAIL-resistant
HT-29, A549 and HepG2 cells growth via inhibition of
NF-κB activity [26, 43] . Our present results showed that
tectochrysin further inhibited TRAIL-inactivated NF-κB
activity, as well as expression of p50 and p-IκB in HT-29
(resistant colon cancer cell), A549 (resistant lung cancer
cell) and MCF-7 (resistant breast cancer cell). Therefore,
tectochrysin inhibits colon cancer cell growth and has
the potential to overcome chemotherapy resistance.
TRAIL is a potential anticancer agent because of its cap-
acity to kill selectively cancer cells without toxic effects
on normal cells, and thus many chemoresistant cancer
cells are resistant to TRAIL [44]. Previous studies have
reported that natural compounds enhanced TRAIL in-
duced apoptotic cell death in TRAIL-resistant cancer
cells. Curcumin, a natural flavonoid compound, can syn-
ergistically induce apoptosis in three TRAIL-resistant
breast cancer cell lines [45]. We found that tectochrysin
enhanced TRAIL induced cell growth inhibition up to
65.8 % in HT-29 TRAIL-resistant colon cancer cells. We
also demonstrated that the synergistic effects of tecto-
chrysin and TRAIL on the activation of caspase-3 cleav-
age and the expression of DR4 in the TRAIL-resistant
cancer cells (HT-29, A549 and MCF-7). Combination
index values of A549 and HT-29 cells were 0.021, and
MCF-7 was 0.034. These results indicated that tecto-
chrysin enhances TRAIL-induced apoptotic cell death
through the over-expression of DR4 as well as the
down-regulation of anti-apoptotic protein expression via
inhibiting NF-κB pathways.
Fig. 6 Effect of tectochrysin on the tumor growth in HCT116 xenografts in vivo model. HCT116 xenografts mice were i.p treated with
tectochrysin (5 mg/kg twice a week) for 3 weeks. a Tumor images (left, vehicle; right, tectochrysin 5 mg/kg), weights and volumes. The data are
expressed as the mean ± SD of ten mice. *P < 0.05 compared with the vehicle mice. b Tumor extracts were analyzed by Western boltting.
Samples (20 μg/lane) were resolved on 10 % or 15 % SDS-PAGE and detected with antibodies against cleaved caspase-3, DR3, DR4, p50, p65,
β-actin, and Histone-H1. β-actin and histone-H1 proteins were used as internal controls. c DNA binding activity of NF-κB was determined by EMSA
in nuclear extracts from tumor tissue of mice, as described under Methods. d Immunohistochemistry was used to determine expression levels of H&E,
PCNA, DR3, cleaved capase-3, and p50 in tumor tissue of mice as described in Methods. Each figures represent for three animals, and each band is
representative for three experiments. Values below the band are average of band density
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In a xenograft nude mouse, tumor weight and volume
in mice treated with tectochrysin at 5 mg/kg doses were
57.9 % and 46.4 % of the vehicle group, respectively. The
expression of DR3, DR4 and cleaved caspase-3 was also
significantly increased in tectochrysin treated mice, but
DNA binding activities of NF-κB and translocation of
p50 and p65 into the nucleus were clearly lowered in
tumor tissues treated with tectochrysin. Silibinin and
wogonin, different flavonoids, inhibited HCT116 colon
cancer cells with IC50 value of 75 μg/mL and 42.6 μg/mL
[46, 47]. However, in the present study, tectochrysin inhib-
ited human colon cancer cells growth with IC50 value of
8.4 μg/mL and 6.3 μg/mL. In in vivo study, silibinin
(200 mg/kg) or aciculatin (30 mg/kg), inhibited human
colon tumor growth about 49.1 %, 40 % respectively
[48, 49]. However, 5 mg/kg tectochrysin showed 48.1 %
inhibition in HCT116 human colon cancer growth. These
data indicate that tectochrysin could be more for chemo-
therapeutics compared to other flavonoids. Moreover, we
also found that tectochrysin could be a well absorbed
compound as a high degree of plasma protein binding
compound as determined by the ADME prediction
program (pre ADME version 1.0.2). Several drug-likeness
predictions such as Lipinski’s, Lead-like, CMC-like, 2.91 as
sklogP value and WDI-like rules indicate that this com-
pound is suitable to be used as a drug. Toxicity prediction
indicated that there is no toxic effect by this compound.
In conclusion, the current study showed that tectochrysin
exerts its cell growth inhibitory effects through inhibition
of NF-κB and enhancement of DR expression in human
colon cancer cells, and enhances sensitivity of TRAIL-
resistant cancer cells, suggesting that tectochrysin can be
a useful agent for the treatment of colon cancer as well as
an adjuvant agent for chemo-resistant cancer.
Methods
Chemicals
We subsequently identified the key compound according
to activity-guided purification, as described elsewhere
[25]. The active principle was obtained as white amorph-
ous powder with physico-chemical properties of ESI-MS
m/z: 291 [M +Na]+; 1H-NMR (500 MHz, CDCl3): ,
13C-
NMR (100 MHz, CDCl3). The structure of tectochrysin
was identified by comparison with its physico-chemical
and spectroscopic data reported by an investigator [50]
as described elsewhere [25].
Cell culture
SW480, HCT116, HT-29, A549 and MCF-7 cells were
obtained from the American Type Culture Collection
(Manassas, VA). SW480, HCT116, HT-29, A549 and
MCF-7 cells were cultured in RPMI 1640 and DMEM
medium supplemented with 10 % fetal bovine serum
(FBS) and penicillin/streptomycin (100 U/mL). Cell
cultures were then maintained at 37 °C in a humidified
atmosphere with 5 % CO2. The human colon CCD-18co
normal cell was also obtained from the Korea Cell Line
Bank and were grown in DMEM medium with 10 %
fetal bovine serum, 25 mM HEPES and penicillin/
streptomycin (100 U/mL) at 37 °C in a humidified
atmosphere with 5 % CO2.
MTT assay and evaluation of apoptotic cell death
Each cell line (1 104$$1\times {10}^4$$ cells) was incu-
bated in 200 μl of RPMI 1640, DMEM medium with tec-
tochrysin (concentrations ranging from 1, 5, 10 μg/mL) in
a 96-well flat-bottomed plate in triplicate. After incubation
for 72 h at 37 °C, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma, St Louis, MO, USA)
diluted in RPMI 1640, DMEM medium were added to
each well and incubation was carried out for 90 min. The
supernatant was then discarded and the crystal products
were eluted with DMSO (200 μL/well; Sigma, St Louis,
MO, USA). Colorimetric evaluation was performed with a
spectrophotometer at 540 nm. The apoptosis assay was
first performed by using DAPI staining. SW480 and
HCT116 human colon cancer cells were cultured with
concentrations of tectochrysin (5 μg/mL), and induction
of apoptotic cell death was evaluated after 24 h. Tunel
assay was done as described previously [51].
Western blot analysis and gel electromobility shift assay
Western blot analysis was performed as described previ-
ously [25]. The membranes were immunoblotted with the
following primary antibodies: mouse monoclonal antibodies
directed against Fas, Bax, p65, p-IκB, cytochrome-C, β-
actin, and Histone-H1 (1:1000 dilutions; Santa Cruz Bio-
technology), and rabbit polyclonal antibodies directed
against DR3, DR4, Bid, p50, and IκB (1:1000 dilutions;
Santa Cruz Biotechnology), and against c-IAP1, XIAP, Bcl-
2, cleaved caspase-3, -8, -9 and PARP (1:1000 dilutions; Cell
Signaling Technology, Beverly, MA). Immunoreactive pro-
teins were detected with the Enhanced Chemiluminescence
Western blotting detection system (Amersham Pharmacia
Biotech, Inc., Buckinghamshire, UK). Gel electromobility
shift assay (EMSA) was done as described previously [25].
The relative density of the protein bands was scanned by
densitometry using My Image and quantified by Labworks
4.0 software (UVP, Inc., California, USA).
Transfection
Colon cancer cells (SW480, HCT116 7 103 $$7\times
{10}^3$$ cells/well) were plated in 96-well plates and
transiently transfected with 0.4 μg of the empty vector
or the constitutively activated 100 nM of negative
siRNA, DR3, DR4 or Fas siRNA per well, using a mix-
ture of plasmid and the WelFect-EX PLUS reagent in
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OPTI-MEM, according to the manufacturer’s specifica-
tion (WelGENE, Seoul, Korea). The p50 mutant (Vp50A,
valine 412 was substituted with Alanine) plasmid was also
transfected with welfect-EX plus reagent in OPTI-MEM
according to the manufacturer׳s specification (WelGENE,
Seoul, Korea). DR3 siRNA seq. 5’-GAAGCCCUAA-
GUACGGUUAtt; DR4 siRNA seq. 5’-CUCUGAUGCU-
GUUCUUUGAtt; Fas siRNA seq. 5’ -GA
ACCCGUGUUUGCAAUCAtt.
Pull-down assay
Western blot analysis was performed as described previ-
ously [25]. The cell lysate or NF-κB (p50) recombinant
protein (Abnova, Taipei, Taiwan) were mixed with
tectochrysin-conjugated Sepharose 6B or Sepharose 6B at
4 °C for 24 h. The beads were then washed three times
with TBST. The bound proteins were eluted with SDS
loading buffer. The proteins were then resolved by SDS-
PAGE followed by immunoblotting with antibodies against
NF-κB p50 (1:1000 dilution, Santa Cruz Biotechnology).
Docking procedure for NF-κB with tectochrysin
Molecular docking studies were performed using Auto-
dock VINA. NF-κB was obtained from the X-ray crystal
structure of NF-κB p50/p65 heterodimer complexed to
the immunoglobulin κB DNA. (PDB ID: 1VKX). Only
p50 of the heterodimer NF-κB structure of p50/p65 was
used in the docking experiments and conditioned using
AutodockTools by adding all polar hydrogen atoms. The
grid box was centered on the p50 and the size of the
grid box was adjusted to include the whole monomer.
Docking experiments were performed at various ex-
haustiveness values of the default, 24, and 48. After the
best binding mode was chosen, another round of dock-
ing experiments were performed with the grid box
re-centered at the binding site of the best ligand-binding
mode with its grid box size of 30 × 30 × 30.
Antitumor activity study in vivo xenograft animal model
Five-week-old male BALB/c athymic nude mice (n = 10/
group) were purchased from Japan SLC, Inc. (Shizuoka,
Japan) and housed in clean specific pathogen free (SPF)
rooms. All experiments were approved and carried out ac-
cording to the Guideline for the Care and Use of Animals
of the Chungbuk National University Animal Care Com-
mittee (CBNU-278-11-01). HCT116 cancer cells were
injected subcutaneously (1 × 107 cells/0.1 mL PBS/animal)
into the lower right flanks of mice. After 14 days, when
the tumors had reached an average volume of 200–
300 mm3, the tumor-bearing nude mice were intraperito-
neally injected with tectochrysin (5 mg/kg dissolved in
0.1 % DMSO) twice per week for 3 weeks. In in vitro
experiments, the IC50 value of 8.4 μg/mL in HCT116
appeared, thus the concentration of the drug (5 mg/kg)
was set in animal models. The tumor volumes were mea-
sured with vernier calipers and calculated by the following
formula: (A × B2)/2, where A is the larger and B is the
smaller of the two dimensions.
Immunohistochemistry
All specimens were fixed in formalin and paraffin-enclosed
for examination. Sections 4 μm thick were stained with
Hematoxylin and Eosin (H&E) and immunohistochemistry
as described elsewhere [14].
Data analysis
The data were analyzed using the GraphPad Prism 4 ver.
4.03 software (GraphPad Software, La Jolla, CA). Data
are presented as mean ± SD. The differences in all data
were assessed by one-way analysis of variance (ANOVA).
When the P value in the ANOVA test indicated statis-
tical significal significance, the differences were assessed
by the Dunnett’s test. A value of P < 0.05 was considered
to be statistically significant.
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